Does rapid dose titration affect the hepatic safety profile of Bosentan?

Bosentan Therapy for Pulmonary Arterial Hypertension

Lewis J. Rubin, David B. Badesch, Robyn J. Barst et al. · New England Journal of Medicine · 2002 · 2.7K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study

Richard N. Channick, G Simonneau, Olivier Sitbon et al. · The Lancet · 2001 · 1.5K citations

Medicine, Pharmacology, Pharmacotherapy +13

The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions

Karin Fattinger · Clinical Pharmacology & Therapeutics · 2001 · 505 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Short-Term Oral Endothelin-Receptor Antagonist Therapy in Conventionally Treated Patients With Symptomatic Severe Chronic Heart Failure

Gabor Sütsch, Wolfgang Kiowski, Xiao-Wei Yan et al. · Circulation · 1998 · 290 citations

Medicine, Cardiology, Pharmacology +17

Long-Term Outcome of Bosentan Treatment in Idiopathic Pulmonary Arterial Hypertension and Pulmonary Arterial Hypertension Associated with the Scleroderma Spectrum of Diseases

Reda E. Girgis, Stephen C. Mathai, Jerry A. Krishnan et al. · The Journal of Heart and Lung Transplantation · 2005 · 101 citations

Medicine, Cardiology, Clinical Sciences +11